Beyond the Bandage: How Aeris Biosciences is Engineering a New Future for Healing

CLEVELAND, OH – July 28, 2026 – In the world of medical innovation, a name change is rarely just about branding. It often signals a fundamental evolution in strategy and ambition. Such is the case with Auxilium Health, a promising regenerative medicine firm that today becomes Aeris Biosciences™. This rebranding is more than a new logo; it’s a declaration of an expanded vision for a technology that aims to fundamentally change how the human body heals.

For decades, the materials used to mend our bodies—from wound dressings to orthopedic implants—have been largely passive. They are static structures that the body must heal around, sometimes successfully, and other times with complications like infection or poor integration. Aeris Biosciences is challenging this paradigm with a new class of biomaterials designed not just to occupy space, but to actively orchestrate the healing process.

The Architecture of Regeneration

At the heart of Aeris Biosciences' innovation is its proprietary “Aer™” platform, a class of three-dimensional bioaerogels. These are not your typical bandages or implants. Imagine an incredibly lightweight, porous scaffold, engineered at the micro and nanoscale to mimic the body's own extracellular matrix—the natural framework that holds cells together. This intricate architecture is the key to the company's dual-pronged strategy: welcoming the body's own regenerative cells while actively repelling harmful bacteria.

The company calls this winning the “race for the surface.” When any foreign material is introduced into the body, a competition begins. Will healing cells colonize the surface first, or will pathogenic bacteria form a resilient, drug-resistant biofilm? Biofilm-related infections are a scourge of modern medicine, complicating recoveries and driving up healthcare costs. Aeris's bioaerogels are designed with a specific surface chemistry and architecture that makes them inhospitable to bacterial attachment. Crucially, this is achieved structurally, without relying on antibiotics, a vital feature in an era of mounting antimicrobial resistance. By giving the body’s own cells a head start, the material creates an environment where regeneration can triumph over infection.

"The name is new, but the promise behind it isn't," said Isaiah Kaiser, PhD, Founder and CEO of Aeris Biosciences™. "We built this company to restore human health, and every product we develop still answers that... Aeris is our commitment to meet that moment with biomaterials that actively guide the body forward, and to keep building toward a future where healing is something clinicians can count on."

A Strategic Pivot in a Multi-Billion Dollar Market

The rebranding from Auxilium Health, which initially focused on soft-tissue healing, to Aeris Biosciences reflects the true breadth of its platform. The company is now publicly staking its claim in the far larger and more complex fields of bone regeneration and localized therapeutic delivery. This strategic expansion is timed to capitalize on a rapidly growing market. Projections show the global market for tissue engineering and biomaterial-based regenerative medicine soaring, with some estimates predicting it will exceed $8 billion by 2034, growing at a compound annual growth rate of over 30%.

Investor confidence appears strong. The company's recent closure of an oversubscribed $3.4 million seed funding round, following a $1.5 million pre-seed round a year prior, provides the capital needed to navigate the rigorous regulatory landscape. These funds are earmarked to advance its lead product toward FDA clearance and into first-in-human clinical studies. While the specifics of the lead product remain under wraps, the company’s progress signals a clear trajectory from the laboratory to the clinic.

This move from a niche focus to a broad platform technology company is a classic, albeit ambitious, play in the biotech world. By rebranding, Aeris is sending a clear message to partners, investors, and the medical community: its technology is not a single product, but a foundational material science platform with the potential to generate a pipeline of solutions across multiple high-need clinical areas.

Redefining the Patient Experience

Beyond the science and market strategy lies the ultimate purpose of medical technology: improving patient lives. For the millions of people suffering from chronic, non-healing wounds, complex fractures, or implant-associated infections, the promise of Aeris's technology is profound. A biomaterial that actively promotes healing while preventing infection could dramatically reduce recovery times, minimize the need for revision surgeries, and lower the risk of debilitating complications.

Consider the diabetic foot ulcer, a notoriously difficult-to-treat wound that can lead to amputation, or the periprosthetic joint infection, a devastating complication of hip or knee replacement surgery. In these scenarios, a material that can transform a biofilm-stalled wound into a regenerative environment or create a seamless, infection-resistant bond between an implant and bone would be revolutionary. It represents a shift from reactive treatment—managing infections after they occur—to proactive prevention built directly into the healing scaffold itself.

As Dr. Kaiser noted, "Behind every wound, every implant, every difficult recovery is a person waiting to heal, and the people beside them waiting too." This human-centered perspective is at the core of the company's mission. Faster, more predictable healing isn't just a clinical metric; it's more days of mobility, less time in pain, and a quicker return to a full life.

An Ecosystem of Support

Innovations of this magnitude do not emerge from a vacuum. Aeris Biosciences is a product of a robust and supportive ecosystem that bridges public funding, academic excellence, and regional industrial strength. Headquartered at the Cleveland Clinic's Global Innovation Center, the company is immersed in an environment of clinical expertise and collaborative research.

Crucially, its work is bolstered by foundational support from public and private institutions. Grants from the National Science Foundation (NSF) provided early-stage validation, a critical endorsement for high-risk, high-reward science. Support from the Ohio Department of Development and the Polymer Industry Cluster highlights a strategic regional commitment to fostering advanced manufacturing and biotechnology. This convergence of federal research funding, state-level economic development, and local industry expertise creates the fertile ground necessary for a deep-tech startup to translate a scientific breakthrough into a commercially viable and socially impactful enterprise.

As Aeris Biosciences moves forward under its new name, it carries the promise of its science and the strength of its supporting network. The journey from a laboratory concept to a standard of care is long and arduous, but the company is methodically assembling the technology, strategy, and resources needed to make that journey. For patients and clinicians, it represents a tangible step toward a future where healing is not left to chance, but is actively and intelligently guided.